A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure
Phase of Trial: Phase IV
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Saxagliptin (Primary) ; Sitagliptin (Primary)
- Indications Diabetes mellitus; Heart failure
- Focus Pharmacodynamics
- Acronyms MEASURE-HF
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 12 Jan 2017 Status changed from not yet recruiting to recruiting.
- 24 Oct 2016 Planned End Date changed from 1 Oct 2018 to 1 Sep 2018.